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ABSTRACT
Plasminogen activator inhibitor-1 (PAI-1) is a biomarker of thrombosis. Adipose and vascular tissues are among the 
major sources of PAI-1 production. Previous studies indicated that fat deposits mediate increased cardiovascular risk 
among obese individuals. We investigated the immunohistochemical (IHC) expression of PAI-1 in adipose and vascular 
tissues from the omentum and the subcutaneous tissue. The pathology samples were selected from 37 random patients 
who underwent elective abdominal surgery between 2008-2009. PAI-1 expression was semi-quantitatively scored and 
compared between the groups. Significant differences were noted in the IHC expression of PAI-1 between the omental 
and the subcutaneous adipose tissues (1.1 ± 0.8 versus 0.8 ± 0.6, respectively (p=0.05)). Adipose tissue displayed higher 
IHC expression of PAI-1 compared to vascular wall tissue in both omentum and subcutaneous sections (1.1 ± 0.8 versus 
0.5 ± 0.9 (p=0.004), and 0.8 ± 0.6 versus 0.4 ± 0.6 (p=0.003), respectively). In conclusion, our study compared PAI-1 
expression in the omentum versus the subcutaneous tissue and adipose versus vascular tissues. IHC expression of PAI-1 
level was significantly higher in the omental adipose tissue compared to the subcutaneous adipose tissue. Adipose tissue 
displayed significantly higher PAI-1 expression than vascular tissue. The study elucidates the biological differences of 
adipose and vascular tissue from subcutaneous versus omental sections. 
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INTRODUCTION
Plasminogen activator inhibitor (PAI-1) is a 
member of the superfamily of serine-protease 
inhibitors and plays a crucial role in the inhibition of 
both tissue and urinary type of plasminogen activators.1 
PAI-1 is produced in various cells as the liver, brain, 
muscle, and adipocytes. PAI-1 production is stimulated 
by various cytokines such as IL-6, TNF-a, and TGF-b.2,3 
Basic and clinical science studies confirmed that obesity 
and metabolic syndrome are associated with alterations 
in the fibrinolytic system and supported the hypothesis 
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that an increased PAI-1 expression by the adipose and 
vascular tissues might contribute to cardiovascular 
disease progress.1,4,5
The volume of adipose tissue, but also the types 
of adipose tissue is associated with the development 
of cardiovascular risk.6,7 Adipocytes display biological 
differences based on their origin. The visceral adipose 
tissues were associated with increased risk of major 
cardiovascular events compared with the adipose 
tissue of the subcutaneous.6,8 In this study, we 
examined immunohistochemical (IHC) expression of 
PAI-1 in surgical pathology samples from patients who 
underwent elective abdominal surgery.
METHODS
Surgical Pathology Samples
The study was approved by the Marmara 
University Medical School Institutional Review Board. 
The pathological samples were selected retrospectively 
from the archives of Marmara University Pathology 
Department. Randomly 37 patients were selected 
who underwent elective abdominal surgery for various 
clinical indications between 2008 and 2009 (Table 1).
The types and indicat ions for abdominal 
surgery included splenectomy for thalassemia and 
immune thrombocytopenia, lymph node resection 
for Non-Hodgkin’s lymphoma, total pancreatectomy 
and gastrectomy for cancer, and colon resection for 
ulcerative colitis. Nearly 20% of patients had the 
history of diabetes mellitus. Since the study samples 
were selected retrospectively, no informed consent 
was required.
Immunohistochemical Expression
IHC express ion of PAI-1 staining (Rabbit 
anti-human PAI-1 antiserum, Molecular Innovations, 
Inc) was performed. Three to five fields were evaluated 
per section for PAI-1 expression. Adipose tissue from 
the omentum and the subcutaneous tissue was 
removed immediately and cut in 2 mm thick slices. 
These were fixed in 10% formalin and embedded in 
paraffin followed by the IHC reaction. IHC expression 
of PAI-1 semi-quantitatively scored from the adipose 
and vascular wall tissues from the omentum and 
subcutaneous. Blinded pathologists selected at least 
three pathological slides per block at 10X (magnification) 
and analyzed on the cellularity and density of PAI-1 
expression. Then, BX51 OlympusR microscopy was used 
to count cells that expressed PAI-1. A visual grading 
scale (0 to 3) was used for the assessment of the 
intensity IHC expression of PAI-1: Score “0” represented 
no expression, score “1” represented mild expression, 
score “2” represented moderate expression, and score 
“3” or more represented the most extensive PAI-1 
expression.9 The average score was calculated for each 
pathological samples. Comparison between groups 
and semi-quantitative scores were performed for 
statistical evaluation. A value of p<0.05 was considered 
statistically significant.
RESULTS
Significant differences were noted in the IHC 
expression of PAI-1 between the omental and the 
subcutaneous adipose tissues. Mean ± standard 
deviation scores of IHC expression of PAI-1 for 
the omental versus the subcutaneous adipose 
tissue were 1.1 ± 0.8 versus 0.8 ± 0.6 (p=0.05). 
The omental adipose tissue also displayed higher IHC 
expression of PAI-1 compared to omental vascular 
wall (1.1 ± 0.8 versus 0.5 ± 0.9 (p=0.004)). Similarly, 
the subcutaneous adipose tissue displayed higher 
IHC expression of PAI-1 compared to subcutaneous 
vascular wall (0.8 ± 0.6 versus 0.4 ± 0.6 (p=0.003)), 
while the IHC expression of PAI-1 semi-quantitative 
scores were similar between the omental versus the 
subcutaneous vascular wall tissues (0.5 ± 0.9 versus 
0.4 ± 0.6 (p=0.32)) (Figures 1-3).
DISCUSSION
Adipose t i ssue has  a  cruc ia l  ro le  in  the 
development of cardiovascular diseases. Adipose 
tissues secrete adipokines. Considerable interest 
remains in understanding the endocrine role of 
Table 1. Characteristics of the study sample as median 
age and gender
Age (years) Females (%)
Mean ± SD 53 ± 14 43
Median (IR) 55 (26)
IR = interquartile range; SD = standard deviation.
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Figure 2. Scoring of IHC PAI-1 expression in adipose tissue.
Figure 3. Scoring of IHC PAI-1 expression in vascular tissue.
Figure 1. Comparison of IHC PAI-1 expression between omental and subcutaneous tissues. IHC = immunohistochemical; 
PAI-1 = plasminogen activator inhibitor-1.
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adipokines. Adipocyte-derived PAI-1 can serve 
as a link between the increased body fat of the 
obese and the cardiovascular risk. The biological 
importance of the PAI-1 molecule is not limited 
to the coagulation-fibrinolysis cascade but is also 
demonstrated in many physiological and pathological 
processes, including obesity, inflammation, insulin 
resistance, and malignancy.4,10 PAI-1 is produced 
and released by adipose tissues; however, the PAI-1 
production varies not only with the adipose tissue 
burden but also with the type of the adipose tissue.11,12 
In this context; the biological differences of adipose 
tissues, subcutaneous versus omentum, have been 
demonstrated in favor of different gene expression, 
secretion of various inflammatory markers, growth 
factors, and fibrinolysis agents.13-16
Several ex-vivo human studies showed an increased 
production of PAI-1 by the visceral adipose tissues 
compared with the subcutaneous adipose tissues.17-19 
However, conflicting data exist in the literature about 
the biological differences between the omental versus 
the subcutaneous adipose tissues. Van Harmelen et al.20 
reported higher PAI-1 mRNA expression and PAI-1 
antigen secretion by the subcutaneous adipose 
tissue compared with the visceral adipose tissue. 
He et al.21 reported that no differences exist in PAI-1 
expression between the omental and the subcutaneous 
adipose tissue; however, yet after incubation, a higher 
expression of PAI-1 was observed in the omental than 
the subcutaneous adipose tissue. Our study extends the 
evidence by using IHC and demonstrates the relation 
of increased PAI-1 production by the visceral origin 
adipose tissues (omentum). Our observations might be 
supportive for the prior findings by several other groups. 
Hardy et al.22 showed that inflammation in the omental 
adipose tissue is associated with insulin resistance. 
O’Connel et al.23 indicated that omental adipocyte size 
was an indicator of liver fibrosis, metabolic disease, 
and possibly progression from hepatic steatosis to 
fibrosis. Yang et al.24 reported that mesentery adipose 
depot played a pivotal role in obesity-related diabetes. 
Harman-Boehm et al.25 reported that preferential 
macrophage infiltration into the omental adipose tissue 
compared to the subcutaneous adipose tissue, among 
the obese population, might be the link between 
with increased risk of coronary artery disease and 
central obesity
Accumulated fat  and enhanced adipose 
tissue-derived PAI-1 might induce fibrosis and chronic 
inflammation. As a potential explanation, TGF-β is 
a strong inducer of PAI-1 expression.26 A previous 
study reported that the molecular mechanism involves 
tissue-specific TGF-β response to Ang II infusion; hence 
the PAI-1 response to TGF-β can display tissue-specific 
characteristics.27
Our study has several l imitations. It was a 
retrospective surgical pathology sample analysis 
of PAI-1 expression in the tissues of patients who 
underwent elective intra-abdominal surgery. There 
was no blinding in the pathology assessment of IHC 
expression of PAI-1. Therefore, the PAI-1 expression in 
different tissues can vary based on patients’ baseline 
vascular risk characteristics. We did not measure the 
plasma PAI-1 antigen and activity levels; therefore, we 
cannot assess the overall fibrinolytic activity in these 
patients. The sample size was relatively small, and this 
could be related to the restrictive eligibility criteria 
and availability of the tissue samples to assess PAI-1 
expression. However, our study directly compares the 
IHC expression of PAI-1 in different tissues. We did 
find significant differences in IHC expression of PAI-1 
in different tissue segments. We believe our data 
can provide clinicians with a rationale for a detailed 
assessment of the patients with cardiovascular risk.
In conclusion, IHC staining scores displayed higher 
levels of PAI-1 expression in the adipose tissues than 
the vascular wall and higher levels of PAI-1 expression 
in the omental adipose tissues than the subcutaneous 
adipose tissues. Future studies in large cohorts 
involving patients’ characteristics, plasma PAI-1 levels, 
and follow-up data would be more explanatory for the 
role of PAI-1 in cardiovascular and metabolic diseases.
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